skip to content

Centre for Advanced Photonics and Electronics

 
GSK logo

CAPE is pleased to welcome GSK Consumer Healthcare as our new CAPE Partner from April 1st 2021. Within CAPE, the GSK collaboration will focus on science and technology that helps improve understanding of human health and the ways it can be positively influenced.

Tom Watt, Research Development Director, Connected Devices and Systems at GSK explained why GSK decided to join CAPE:“GSK’s mission is to help people do more, feel better and live longer – to meet this challenge has always required world class science and we are incredibly excited to continue this by partnering with the University of Cambridge through the CAPE initiative.

The interface of technology, engineering and healthcare is currently one of the most challenging, rewarding and rapidly developing areas of research; we look forward to the innovations and insights that CAPE researchers can bring.

Professor Daping Chu, Director of CAPE, commented: We are delighted that GSK Consumer Healthcare is joining the CAPE Partnership. The opportunity to collaborate with a world-leading company to expand CAPE activity in systems and devices for health will bring significant benefit to our research community and help lay the foundations for improved understanding, new devices and treatments and future healthcare technology breakthroughs.

About GSK Consumer Healthcare

GSK’s world-leading Consumer Healthcare business combines science and consumer insights to create innovative everyday healthcare brands that consumers trust and experts recommend for oral health, pain relief, cold, flu and allergy, digestive health and vitamins, minerals and supplements.

Their portfolio of loved and trusted brands includes Sensodyne, parodontax, Polident, Advil, Voltaren, Panadol, Otrivin, Theraflu and Centrum. It is one of the world’s leading over-the-counter (OTC) healthcare companies with number one positions in a number of markets, including the US, India and Germany. The business generated sales of £10 billion in 2020